Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CTMX
Strong SellSinkerCytomX Therapeutics, Inc. · Healthcare · United States · $699M · Avg Vol: $10M/d
COMPANY DESCRIPTION
CytomX Therapeutics, Inc. is a clinical-stage oncology company pioneering the development of Probody therapeutics, a novel class of antibody-based drugs designed for tumor-specific activation. This proprietary technology aims to enhance therapeutic efficacy and reduce systemic toxicity compared to conventional antibodies, offering a potential competitive advantage in the cancer treatment landscape.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.2M | 101.2M | 138.1M | 76.2M | 12.8% | 18.3M | 25.0M | 25.3M | -42.3% |
| EPS | -0.46 | -0.00 | 0.14 | -0.15 | — | -0.57 | -0.39 | -0.47 | — |
| Shares | 217.7M | 217.7M | 217.7M | 170.2M | -21.8% | 217.9M | — | — | — |
| Debt | 18.1M | 14.0M | 9.4M | 4.2M | -38.3% | 5.7M | — | — | — |
| Equity | -85.8M | -47.4M | -0.5M | 99.0M | — | — | — | — | — |
| Op CF | -110.8M | -56.0M | -86.2M | -75.6M | — | -82.4M | — | — | — |
| Inv CF | 98.3M | -150.7M | 99.7M | -59.7M | — | — | — | — | — |
| Fin CF | 0.6M | 30.2M | 7.5M | 110.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTMX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc.(you) | $699M | 12 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 10 | Strong Sell |
| PHAT | Phathom Pharmaceuticals, Inc. | $743M | 14 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $701M | 8 | Strong Sell |
| STTK | Shattuck Labs, Inc. | $707M | 17 | Strong Sell |
| RGNX | REGENXBIO Inc. | $638M | 8 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $595M | 10 | Strong Sell |
| CABA | Cabaletta Bio, Inc. | $529M | 11 | Strong Sell |
| 950260.KQ | Ingenia Therapeutics Inc. | $649M | 7 | Strong Sell |
| SGP | SpyGlass Pharma, Inc. | $884M | 14 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%